{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:45:50Z","timestamp":1781624750276,"version":"3.54.5"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Popul Health Metrics"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Non-Hodgkin lymphoma (NHL) is the most common hematologic cancer in the US. Validated projections of NHL cases are important for various stakeholders. The study aimed to identify and characterize methods forecasting NHL incidence, prevalence, and number of treatment eligible patients with NHL by line of therapy (LoT). In addition, methods evaluating the performance of cancer forecasting methods were also identified and utilized in selecting the most robust projection method applicable to NHL disease setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive search was conducted in MEDLINE and EMBASE databases, covering January 2002 to April 2024 for English-language studies reporting methods evaluating cancer count estimation and NHL projection methods. Study characteristics were extracted and described. Criteria was developed to identify the most appropriate methods for evaluating projection methods. The identified methods of evaluation were then adopted to measure the accuracy of NHL projection methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-nine articles met the inclusion criteria for methods of evaluation, with 58.6% evaluating projection methods through calculating relative difference between observed and predicted case numbers. The most appropriate methods found for evaluating cancer incidence and prevalence projection were the average absolute relative deviation (AARD) and percent variation (VAR%), respectively. These methods were applied to projection methods identified through literature review to determine the robust method to project incidence and prevalence. Among twenty-six articles met the inclusion criteria for NHL projection methods, the joinpoint regression model was determined as the most robust method for projecting NHL incidence in the US, with the lowest AARD (1.6%). The projection method with assumptions of a 52.8% cure rate, a cure beginning ten years post-diagnosis, and all surviving patients cured after 20 years was identified as the most robust method for projecting NHL prevalence, with the lowest VAR% (8.3%). Unfortunately, due to the limited number and quality of studies, no robust method was identified for projecting the number of treatment-eligible NHL patients by LoT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This review identified the most appropriate method of evaluating projection methods, and identified methods for projecting NHL incidence and prevalence in the US. Nevertheless, further research is needed to validate and project the number of treatment-eligible NHL patients by LoT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12963-025-00415-8","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:58:23Z","timestamp":1761040703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation and forecasting methods to estimate number of patients with non-Hodgkin lymphoma: a systematic literature review"],"prefix":"10.1186","volume":"23","author":[{"given":"Dan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxia","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmneh M.","family":"Sineshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"415_CR1","unstructured":"American Cancer Society. What Is Non-Hodgkin Lymphoma? 2024 [updated February 15, 2024. Available from: https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/what-is-non-hodgkin-lymphoma.html"},{"key":"415_CR2","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Non-Gosgkin Lymohoma 2024 [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"issue":"9","key":"415_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jnci\/djad086","volume":"115","author":"AB Mariotto","year":"2023","unstructured":"Mariotto AB, Feuer EJ, Howlader N, Chen H-S, Negoita S, Cronin KA. Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic. JNCI: J Natl Cancer Inst. 2023;115(9):1109\u201311.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"415_CR4","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"415_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"415_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Arnason JE. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the united States and Western europe: population-level projections for 2020\u20132025. Leuk Lymphoma. 2022;63(1):54\u201363.","journal-title":"Leuk Lymphoma"},{"key":"415_CR7","doi-asserted-by":"crossref","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617\u2009\u2013\u200929.","DOI":"10.1002\/ajh.26151"},{"issue":"11","key":"415_CR8","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/ajh.27075","volume":"98","author":"M Tavakkoli","year":"2023","unstructured":"Tavakkoli M, Barta SK. 2024 update: advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol. 2023;98(11):1791\u2013805.","journal-title":"Am J Hematol"},{"issue":"4","key":"415_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"issue":"5","key":"415_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638\u201356.","journal-title":"Am J Hematol"},{"issue":"8","key":"415_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806\u201313.","journal-title":"Am J Hematol"},{"issue":"3","key":"415_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1200\/JCO.22.01780","volume":"41","author":"O Hermine","year":"2023","unstructured":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell lymphoma network. J Clin Oncol. 2023;41(3):479\u201384.","journal-title":"J Clin Oncol"},{"key":"415_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241232331","author":"J Lu","year":"2024","unstructured":"Lu J, Do B, Primeaux B. Evaluation of second-generation Bruton\u2019s tyrosine kinase inhibitors for the treatment of mantle cell lymphoma. J Oncol Pharm Pract. 2024. https:\/\/doi.org\/10.1177\/10781552241232331.","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 1","key":"415_CR14","first-page":"S1","volume":"11","author":"B M\u00f8ller","year":"2002","unstructured":"M\u00f8ller B, Fekjaer H, Hakulinen T, Tryggvad\u00f3ttir L, Storm HH, Talb\u00e4ck M, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev. 2002;11(Suppl 1):S1-96.","journal-title":"Eur J Cancer Prev"},{"key":"415_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-2458-14-102","volume":"14","author":"E Rapiti","year":"2014","unstructured":"Rapiti E, Guarnori S, Pastoors B, Miralbell R, Usel M. Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health. 2014;14:102.","journal-title":"BMC Public Health"},{"issue":"4","key":"415_CR16","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4):e214708\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"415_CR17","doi-asserted-by":"publisher","first-page":"e1092","DOI":"10.1016\/j.clml.2022.08.008","volume":"22","author":"D Chihara","year":"2022","unstructured":"Chihara D, Johnston K, Bolatova T, Szabo S, Kalsekar A, Mutebi A, et al. An epidemiological model to estimate the prevalence of diffuse large B-Cell lymphoma in the united States. Clin Lymphoma Myeloma Leuk. 2022;22(12):e1092\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"415_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14735\/amko201530","volume":"28","author":"L Dusek","year":"2015","unstructured":"Dusek L, Pavl\u00edk T, M\u00e1jek O, B\u00fcchler T, Muzik J, Maluskova D, et al. Estimating cancer incidence, prevalence, and the number of cancer patients treated with antitumor therapy in 2015 and 2020 - analysis of the Czech National cancer registry. Klin Onkol. 2015;28(1):30\u201343.","journal-title":"Klin Onkol"},{"issue":"1","key":"415_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0468-4","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should i conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC Med Res Methodol. 2018;18(1):5.","journal-title":"BMC Med Res Methodol"},{"key":"415_CR20","unstructured":"Appendix A. Guide to the contents of a Cochrane Methodology protocol and review [Available from: https:\/\/handbook-5-1.cochrane.org\/appendix_a\/appendix_a_guide_to_the_contents_of_a_cochrane_methodology.htm"},{"issue":"1","key":"415_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12874-020-0897-3","volume":"20","author":"H Harrison","year":"2020","unstructured":"Harrison H, Griffin SJ, Kuhn I, Usher-Smith JA. Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation. BMC Med Res Methodol. 2020;20(1):7.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"415_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12874-022-01632-7","volume":"22","author":"N Alsadhan","year":"2022","unstructured":"Alsadhan N, Almaiman A, Pujades-Rodriguez M, Brennan C, Shuweihdi F, Alhurishi SA, West RM. A systematic review of methods to estimate colorectal cancer incidence using population-based cancer registries. BMC Med Res Methodol. 2022;22(1):144.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"415_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","volume":"3","author":"Z Munn","year":"2014","unstructured":"Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3(3):123\u20138.","journal-title":"Int J Health Policy Manag"},{"issue":"12","key":"415_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011458","volume":"6","author":"MJ Downes","year":"2016","unstructured":"Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.","journal-title":"BMJ Open"},{"issue":"10062","key":"415_CR25","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","volume":"388","author":"GA Stevens","year":"2016","unstructured":"Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet. 2016;388(10062):e19\u201323.","journal-title":"Lancet"},{"issue":"9","key":"415_CR26","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1055-9965.EPI-20-1727","volume":"30","author":"B Liu","year":"2021","unstructured":"Liu B, Zhu L, Zou J, Chen HS, Miller KD, Jemal A, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: Part I: spatio-temporal modeling for cancer incidence. Cancer Epidemiol Biomarkers Prev. 2021;30(9):1620\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"415_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3109\/02841861003782017","volume":"49","author":"G Engholm","year":"2010","unstructured":"Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint \u00c5, et al. NORDCAN \u2013 a nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725\u201336.","journal-title":"Acta Oncol"},{"key":"415_CR28","unstructured":"U.S. Cancer Statistics Working Group; Department of Health and Human Services; Centers for Disease Control and Prevention and National Cancer Institute. U.S. Cancer Statistics Data Visualizations Tool. 2024 [Available from: https:\/\/www.cdc.gov\/cancer\/dataviz"},{"key":"415_CR29","unstructured":"Cancer Research UK. 2024 [Available from: https:\/\/www.cancerresearchuk.org\/"},{"key":"415_CR30","unstructured":"Northern Ireland Cancer Registry. 2024 [Available from: https:\/\/www.qub.ac.uk\/research-centres\/nicr\/"},{"key":"415_CR31","unstructured":"What is the Manitoba Cancer. Registry? 2024 [Available from: https:\/\/www.cancercare.mb.ca\/Research\/epidemiology-cancer-registry\/what-is-the-manitoba-cancer-registry"},{"key":"415_CR32","unstructured":"The Francim network. 2024 [Available from: https:\/\/www.francim-reseau.org\/"},{"key":"415_CR33","unstructured":"The National Agency for Cancer Registration. Cancer registries and the NACR. 2024 [Available from: https:\/\/nacr.ch\/en\/cancerregistries"},{"key":"415_CR34","unstructured":"Republic of Lebanon Minstry of Public Health. National Cancer Registry (NCR). 2024 [Available from: https:\/\/www.moph.gov.lb\/en\/Pages\/8\/19526\/national-cancer-registry"},{"key":"415_CR35","unstructured":"International Agency for Research on Cancer. Cancer Over Time. 2024 [Available from: https:\/\/gco.iarc.fr\/overtime\/en"},{"key":"415_CR36","unstructured":"Australian Institute of Health and Welfare. National Cancer Control Indicators. 2024 [Available from: https:\/\/ncci.canceraustralia.gov.au\/#"},{"key":"415_CR37","unstructured":"National Cancer Registration Program. 2024 [Available from: https:\/\/ncc.re.kr\/main.ncc?uri=english\/sub04_ControlPrograms02"},{"key":"415_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201464","volume":"13","author":"S Francisci","year":"2023","unstructured":"Francisci S, Tursini F, Dal Maso L, Gigli A, Guzzinati S. Projecting cancer prevalence by phase of care: a methodological approach for health service planning. Front Oncol. 2023;13:1201464.","journal-title":"Front Oncol"},{"issue":"17","key":"415_CR39","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1002\/sim.1481","volume":"22","author":"B M\u00f8ller","year":"2003","unstructured":"M\u00f8ller B, Fekjaer H, Hakulinen T, Sigvaldason H, Storm HH, Talb\u00e4ck M, Haldorsen T. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22(17):2751\u201366.","journal-title":"Stat Med"},{"issue":"1","key":"415_CR40","first-page":"30","volume":"57","author":"LW Pickle","year":"2007","unstructured":"Pickle LW, Hao Y, Jemal A, Zou Z, Tiwari RC, Ward E, et al. A new method of estimating united States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57(1):30\u201342.","journal-title":"CA Cancer J Clin"},{"key":"415_CR41","doi-asserted-by":"publisher","first-page":"418968","DOI":"10.1155\/2011\/418968","volume":"2011","author":"N Mitton","year":"2011","unstructured":"Mitton N, Colonna M, Trombert B, Olive F, Gomez F, Iwaz J, et al. A suitable approach to estimate cancer incidence in area without cancer registry. J Cancer Epidemiol. 2011;2011:418968.","journal-title":"J Cancer Epidemiol"},{"issue":"1","key":"415_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1515\/1557-4679.1411","volume":"8","author":"MJ Rutherford","year":"2012","unstructured":"Rutherford MJ, Thompson JR, Lambert PC. Projecting cancer incidence using age-period-cohort models incorporating restricted cubic splines. Int J Biostat. 2012;8(1):33.","journal-title":"Int J Biostat"},{"issue":"4","key":"415_CR43","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/cncr.27405","volume":"118","author":"L Zhu","year":"2012","unstructured":"Zhu L, Pickle LW, Ghosh K, Naishadham D, Portier K, Chen HS, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012;118(4):1100\u20139.","journal-title":"Cancer"},{"issue":"10","key":"415_CR44","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/sim.4463","volume":"31","author":"R Cl\u00e8ries","year":"2012","unstructured":"Cl\u00e8ries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;31(10):978\u201387.","journal-title":"Stat Med"},{"issue":"3","key":"415_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.canep.2012.12.007","volume":"37","author":"Z Uhry","year":"2013","unstructured":"Uhry Z, Belot A, Colonna M, Bossard N, Rogel A, Iwaz J, et al. National cancer incidence is estimated using the incidence\/mortality ratio in countries with local incidence data: is this estimation correct? Cancer Epidemiol. 2013;37(3):270\u20137.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"415_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canep.2012.10.010","volume":"37","author":"Z Uhry","year":"2013","unstructured":"Uhry Z, Remontet L, Colonna M, Belot A, Grosclaude P, Mitton N, et al. Cancer incidence estimation at a district level without a National registry: a validation study for 24 cancer sites using French health insurance and registry data. Cancer Epidemiol. 2013;37(2):99\u2013114.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"415_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/jjco\/hyt163","volume":"44","author":"K Katanoda","year":"2014","unstructured":"Katanoda K, Kamo K, Saika K, Matsuda T, Shibata A, Matsuda A, et al. Short-term projection of cancer incidence in Japan using an age-period interaction model with spline smoothing. Jpn J Clin Oncol. 2014;44(1):36\u201341.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"415_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2471\/BLT.15.164384","volume":"94","author":"S Antoni","year":"2016","unstructured":"Antoni S, Soerjomataram I, M\u00f8ller B, Bray F, Ferlay J. An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence. Bull World Health Organ. 2016;94(3):174\u201384.","journal-title":"Bull World Health Organ"},{"key":"415_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.canep.2019.02.011","volume":"59","author":"AE Poirier","year":"2019","unstructured":"Poirier AE, Ruan Y, Walter SD, Franco EL, Villeneuve PJ, King WD, et al. The future burden of cancer in Canada: long-term cancer incidence projections 2013\u20132042. Cancer Epidemiol. 2019;59:199\u2013207.","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"415_CR50","doi-asserted-by":"publisher","first-page":"e031331","DOI":"10.1136\/bmjopen-2019-031331","volume":"9","author":"A Earnest","year":"2019","unstructured":"Earnest A, Evans SM, Sampurno F, Millar J. Forecasting annual incidence and mortality rate for prostate cancer in Australia until 2022 using autoregressive integrated moving average (ARIMA) models. BMJ Open. 2019;9(8):e031331.","journal-title":"BMJ Open"},{"issue":"9","key":"415_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.24095\/hpcdp.40.9.02","volume":"40","author":"A Demers","year":"2020","unstructured":"Demers A, Qiu Z, Dewar R, Shaw A. Validation of Canproj for projecting Canadian cancer incidence data. Health Promot Chronic Dis Prev Can. 2020;40(9):267\u201380.","journal-title":"Health Promot Chronic Dis Prev Can"},{"issue":"1","key":"415_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12874-020-01133-5","volume":"20","author":"M Knoll","year":"2020","unstructured":"Knoll M, Furkel J, Debus J, Abdollahi A, Karch A, Stock C. An R package for an integrated evaluation of statistical approaches to cancer incidence projection. BMC Med Res Methodol. 2020;20(1):257.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"415_CR53","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/ije\/dyaa078","volume":"49","author":"Z Uhry","year":"2020","unstructured":"Uhry Z, Chatignoux E, Dantony E, Colonna M, Roche L, Fauvernier M, et al. Multidimensional penalized splines for incidence and mortality-trend analyses and validation of National cancer-incidence estimates. Int J Epidemiol. 2020;49(4):1294\u2013306.","journal-title":"Int J Epidemiol"},{"key":"415_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.738213","volume":"12","author":"F Cheng","year":"2021","unstructured":"Cheng F, Xiao J, Shao C, Huang F, Wang L, Ju Y, et al. Burden of thyroid cancer from 1990 to 2019 and projections of incidence and mortality until 2039 in China: findings from global burden of disease study. Front Endocrinol (Lausanne). 2021;12:738213.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"415_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-021-00248-1","volume":"19","author":"D Redondo-S\u00e1nchez","year":"2021","unstructured":"Redondo-S\u00e1nchez D, Rodr\u00edguez-Barranco M, Ameijide A, Alonso FJ, Fern\u00e1ndez-Navarro P, Jim\u00e9nez-Mole\u00f3n JJ, et al. Cancer incidence estimation from mortality data: a validation study within a population-based cancer registry. Popul Health Metr. 2021;19(1):18.","journal-title":"Popul Health Metr"},{"issue":"2","key":"415_CR56","doi-asserted-by":"publisher","first-page":"437","DOI":"10.31557\/APJCP.2021.22.2.437","volume":"22","author":"Q Luo","year":"2021","unstructured":"Luo Q, Steinberg J, Yu XQ, Caruana M, Canfell K, O\u2019Connell DL. How well have projected lung cancer rates predicted the actual observed rates? Asian Pac J Cancer Prev. 2021;22(2):437\u201345.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"415_CR57","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1055-9965.EPI-20-1780","volume":"30","author":"KD Miller","year":"2021","unstructured":"Miller KD, Siegel RL, Liu B, Zhu L, Zou J, Jemal A, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: Part II: evaluation of incidence and mortality projection methods. Cancer Epidemiol Biomarkers Prev. 2021;30(11):1993\u20132000.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"415_CR58","doi-asserted-by":"publisher","first-page":"1003162","DOI":"10.3389\/fpubh.2022.1003162","volume":"10","author":"J Li","year":"2022","unstructured":"Li J, Chan NB, Xue J, Tsoi KKF. Time series models show comparable projection performance with joinpoint regression: a comparison using historical cancer data from World Health Organization. Front Public Health. 2022;10:1003162.","journal-title":"Front Public Health"},{"issue":"6","key":"415_CR59","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1016\/S2468-2667(22)00090-1","volume":"7","author":"Q Luo","year":"2022","unstructured":"Luo Q, O\u2019Connell DL, Yu XQ, Kahn C, Caruana M, Pesola F, et al. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. Lancet Public Health. 2022;7(6):e537\u201348.","journal-title":"Lancet Public Health"},{"key":"415_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246076","author":"PT Nguyen","year":"2022","unstructured":"Nguyen PT, Saito E, Katanoda K. Long-term projections of cancer incidence and mortality in Japan and decomposition analysis of changes in cancer burden, 2020\u20132054: an empirical validation approach. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14246076.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"415_CR61","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1038\/s41598-024-55230-2","volume":"14","author":"D Bouzon Nagem Assad","year":"2024","unstructured":"Bouzon Nagem Assad D, Gomes Ferreira da Costa P, Spiegel T, Cara J, Ortega-Mier M, Monteiro Scaff A. Comparing the current short-term cancer incidence prediction models in Brazil with state-of-the-art time-series models. Sci Rep. 2024;14(1):4566.","journal-title":"Sci Rep"},{"issue":"10","key":"415_CR62","first-page":"1215","volume":"17","author":"AB Mariotto","year":"2006","unstructured":"Mariotto AB, Yabroff KR, Feuer EJ, De Angelis R, Brown M. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000\u20132020. Cancer Causes Control. 2006;17(10):1215\u201326.","journal-title":"Cancer Causes Control"},{"key":"415_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1114701","volume":"13","author":"E Demuru","year":"2023","unstructured":"Demuru E, Rossi S, Ventura L, Dal Maso L, Guzzinati S, Katalinic A, et al. Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes. Front Oncol. 2023;13:1114701.","journal-title":"Front Oncol"},{"issue":"1","key":"415_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-018-0174-4","volume":"16","author":"D Campbell","year":"2018","unstructured":"Campbell D, O\u2019Day K, Hertel N, Penrod JR, Manley Daumont M, Lees M. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions. Popul Health Metr. 2018;16(1):17.","journal-title":"Popul Health Metr"},{"issue":"12","key":"415_CR65","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jval.2022.05.011","volume":"25","author":"A Nikolaou","year":"2022","unstructured":"Nikolaou A, Hogea C, Samyshkin Y, Maiese EM, Sansbury L, Oguz M, et al. An epidemiology model for estimating the numbers of US patients with multiple myeloma by line of therapy and treatment exposure. Value Health. 2022;25(12):1977\u201385.","journal-title":"Value Health"},{"issue":"17","key":"415_CR66","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"BD Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758\u201365.","journal-title":"J Clin Oncol"},{"issue":"11","key":"415_CR67","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1038\/bjc.2011.430","volume":"105","author":"M Mistry","year":"2011","unstructured":"Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105(11):1795\u2013803.","journal-title":"Br J Cancer"},{"issue":"2","key":"415_CR68","first-page":"71","volume":"31","author":"J Nowatzki","year":"2011","unstructured":"Nowatzki J, Moller B, Demers A. Projection of future cancer incidence and new cancer cases in Manitoba, 2006\u20132025. \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f \u043a\u0430\u043d\u0430\u0434\u044b. 2011;31(2):71\u20138.","journal-title":"\u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f \u043a\u0430\u043d\u0430\u0434\u044b"},{"issue":"11","key":"415_CR69","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"1","key":"415_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7954-12-4","volume":"12","author":"A Shamseddine","year":"2014","unstructured":"Shamseddine A, Saleh A, Charafeddine M, Seoud M, Mukherji D, Temraz S, et al. Cancer trends in Lebanon: a review of incidence rates for the period of 2003\u20132008 and projections until 2018. Popul Health Metr. 2014;12(1):4.","journal-title":"Popul Health Metr"},{"issue":"5","key":"415_CR71","first-page":"2513","volume":"17","author":"A Benhassine","year":"2016","unstructured":"Benhassine A, Khadhra HB, Khiari H, Hsairi M, Elgaaied AB. Incidence trend for non-Hodgkin lymphoma in the North Tunisian population, 1998\u20132009. Asian Pac J Cancer Prev. 2016;17(5):2513\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"415_CR72","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-20-0098","volume":"29","author":"DW Donnelly","year":"2020","unstructured":"Donnelly DW, Anderson LA, Gavin A. Cancer incidence projections in Northern Ireland to 2040. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1398\u2013405.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"415_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2021.101935","volume":"72","author":"JK Cameron","year":"2021","unstructured":"Cameron JK, Baade P. Projections of the future burden of cancer in Australia using bayesian age-period-cohort models. Cancer Epidemiol. 2021;72:101935.","journal-title":"Cancer Epidemiol"},{"key":"415_CR74","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.5888\/pcd18.210006","volume":"18","author":"HK Weir","year":"2021","unstructured":"Weir HK, Thompson TD, Stewart SL, White MC. Cancer incidence projections in the United States between 2015 and 2050. Prev Chronic Dis. 2021;18:E59.","journal-title":"Prev Chronic Dis"},{"issue":"3","key":"415_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056722","volume":"12","author":"J Asasira","year":"2022","unstructured":"Asasira J, Lee S, Tran TXM, Mpamani C, Wabinga H, Jung SY, et al. Infection-related and lifestyle-related cancer burden in Kampala, Uganda: projection of the future cancer incidence up to 2030. BMJ Open. 2022;12(3):e056722.","journal-title":"BMJ Open"},{"issue":"45","key":"415_CR76","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","volume":"156","author":"K Sathishkumar","year":"2022","unstructured":"Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res. 2022;156(45):598\u2013607.","journal-title":"Indian J Med Res"},{"issue":"1","key":"415_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4143\/crt.2013.45.1.15","volume":"45","author":"KW Jung","year":"2013","unstructured":"Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat. 2013;45(1):15\u201321.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"415_CR78","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4143\/crt.2014.46.2.124","volume":"46","author":"KW Jung","year":"2014","unstructured":"Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat. 2014;46(2):124\u201330.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"415_CR79","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4143\/crt.2015.066","volume":"47","author":"KW Jung","year":"2015","unstructured":"Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee DH, et al. Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat. 2015;47(2):142\u20138.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"415_CR80","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4143\/crt.2020.203","volume":"52","author":"KW Jung","year":"2020","unstructured":"Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat. 2020;52(2):351\u20138.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"415_CR81","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4143\/crt.2021.290","volume":"53","author":"KW Jung","year":"2021","unstructured":"Jung KW, Won YJ, Hong S, Kong HJ, Im JS, Seo HG. Prediction of cancer incidence and mortality in Korea, 2021. Cancer Res Treat. 2021;53(2):316\u201322.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"415_CR82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4143\/crt.2022.179","volume":"54","author":"KW Jung","year":"2022","unstructured":"Jung KW, Won YJ, Kang MJ, Kong HJ, Im JS, Seo HG. Prediction of cancer incidence and mortality in Korea, 2022. Cancer Res Treat. 2022;54(2):345\u201351.","journal-title":"Cancer Res Treat"},{"issue":"7","key":"415_CR83","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/1055-9965.EPI-11-0421","volume":"20","author":"PS Rosenberg","year":"2011","unstructured":"Rosenberg PS, Anderson WF. Age-period-cohort models in cancer surveillance research: ready for prime time? Cancer Epidemiol Biomarkers Prev. 2011;20(7):1263\u20138.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"415_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7173","volume":"13","author":"HM Sineshaw","year":"2024","unstructured":"Sineshaw HM, Zettler CM, Prescott J, Garg M, Chakraborty S, Sarpong EM, et al. Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy. Cancer Med. 2024;13(7):e7173.","journal-title":"Cancer Med"},{"issue":"1","key":"415_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01632-6","volume":"10","author":"N Nama","year":"2021","unstructured":"Nama N, Hennawy M, Barrowman N, O\u2019Hearn K, Sampson M, McNally JD. Successful incorporation of single reviewer assessments during systematic review screening: development and validation of sensitivity and work-saved of an algorithm that considers exclusion criteria and count. Syst Rev. 2021;10(1):98.","journal-title":"Syst Rev"}],"container-title":["Population Health Metrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-025-00415-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12963-025-00415-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-025-00415-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:02:55Z","timestamp":1761044575000},"score":1,"resource":{"primary":{"URL":"https:\/\/pophealthmetrics.biomedcentral.com\/articles\/10.1186\/s12963-025-00415-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s12963-025-00415-8","relation":{},"ISSN":["1478-7954"],"issn-type":[{"value":"1478-7954","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}